PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2010-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT00936871
- Locations
- ๐ง๐ช
Pfizer Investigational Site, Bruxelles, Belgium
Study Evaluating Safety Of BMP-655/ACS As An Adjuvant Therapy For Rotator Cuff Repair
- Conditions
- Rotator Cuff Tear
- Interventions
- Biological: BMP-655/ACS or Standard of Care
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT00936559
- Locations
- ๐ณ๐ฑ
Pfizer Investigational Site, Hoofddorp, Netherlands
Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis
- Conditions
- Moderate to Severe Psoriasis
- Interventions
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2012-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00936065
- Locations
- ๐ฐ๐ท
Pfizer Investigational Site, Seoul, Korea, Republic of
Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT00935012
- Locations
- ๐บ๐ธ
University of Chicago Medical Center, Chicago, Illinois, United States
๐บ๐ธEmory University School of Medicine, Atlanta, Georgia, United States
๐บ๐ธThe University of Chicago Medical Center, Chicago, Illinois, United States
A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- Interventions
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT00934089
- Locations
- ๐บ๐ธ
West Coast Clinical Trials, LLC, Cypress, California, United States
๐บ๐ธGlory Medical Group, Garden Grove, California, United States
๐บ๐ธLos Angeles Eye Medical Group, Los Angeles, California, United States
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT00932126
- Locations
- ๐ฆ๐บ
Pfizer Investigational Site, East Melbourne, Victoria, Australia
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1069
- Registration Number
- NCT00932451
- Locations
- ๐บ๐ธ
Ronald Reagen University of California-Los Angeles Medical Center, Los Angeles, California, United States
๐บ๐ธEmory University Hospital Midtown, Atlanta, Georgia, United States
๐บ๐ธEmory Clinic, Atlanta, Georgia, United States
Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2010-07-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 451
- Registration Number
- NCT00932165
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 347
- Registration Number
- NCT00932893
- Locations
- ๐บ๐ธ
UCLA Hematology Oncology, Los Angeles, California, United States
๐บ๐ธThe Ohio State University Hospital East, Columbus, Ohio, United States
๐บ๐ธUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
- Conditions
- Alzheimer's DiseaseHuntington's Disease
- Interventions
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2009-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00931073
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Kalamazoo, Michigan, United States